北京大学学报(医学版) ›› 2022, Vol. 54 ›› Issue (6): 1229-1233. doi: 10.19723/j.issn.1671-167X.2022.06.029

• 短篇论著 • 上一篇    下一篇

唇腺病理阴性干燥综合征患者的临床特点

李红霞1,周雅馨1,王亚飞2,王鹏宇2,吴振彪2,*()   

  1. 1 空军特色医学中心风湿免疫科,北京 100142
    2 空军军医大学第一附属医院风湿免疫科,西安 710032
  • 收稿日期:2022-08-27 出版日期:2022-12-18 发布日期:2022-12-19
  • 通讯作者: 吴振彪 E-mail:wuzhenbiaoxjimmu@163.com
  • 基金资助:
    国家重点研发计划(201KTCL03_03)

红霞 李1,雅馨 周1,亚飞 王2,鹏宇 王2,振彪 吴2,*()   

  • Received:2022-08-27 Online:2022-12-18 Published:2022-12-19
  • Contact: 振彪 吴 E-mail:wuzhenbiaoxjimmu@163.com
  • Supported by:
    National Key Research Development Program of China(201KTCL03_03)

RICH HTML

  

关键词: 干燥综合征, 唇腺, 病理阴性

中图分类号: 

  • R593.2

图1

pSS患者不同唇腺病理改变"

表1

唇腺病理阳性与阴性pSS患者临床指标比较"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
Age/years, $\bar x \pm s$ 48.5±14.9 49.6±14.2 0.440 0.508
Gender (Males/Females), n 5/99 7/106 0.199 0.655
Duration/months, M(P25, P75) 12 (6, 45) 14 (6, 36) 0.802 0.423
Dry mouth 83 (79.8) 83 (73.4) 1.217 0.270
Dry eyes 62 (59.6) 59 (52.2) 1.203 0.273
Parotid swelling 11 (10.6) 15 (13.3) 0.374 0.541
Rampant caries 22 (21.2) 13 (11.5) 3.728 0.054
Arthralgia/Anthritis 16 (15.4) 28 (24.8) 2.957 0.086
Rash 20 (19.2) 22 (19.5) 0.002 0.965
Fever 5 (4.8) 8 (7.1) 0.496 0.481
Hematological involvement 34 (32.7) 34 (30.1) 0.171 0.680
  Leukocytopenia 29 (27.9) 22 (19.5) 2.133 0.144
  Thrombocytopenia 15 (14.4) 15 (13.3) 0.060 0.807
Interstitial pneumonia 10 (9.6) 10 (8.9) 0.038 0.846
Kidney involvement 7 (6.7) 5 (4.4) 0.551 0.458
Nerve involvement 5 (4.8) 9 (8.0) 0.894 0.344
WUSF rate≤0.1 mL/min 46/69 (66.7) 63/80 (78.8) 2.754 0.097
Schirmer test ≤ 5 mm/5 min 43/69 (62.3) 41/77 (53.2) 1.226 0.268
ESSDAI, $\bar x \pm s$ 6.7±5.4 5.7±4.4 3.486 0.063
  ESSDAI<5 44 (42.3) 51 (45.1) 0.176 0.675
  5≤ESSDAI<10 31 (29.8) 42 (37.2) 1.314 0.252
  ESSDAI≥10 29 (27.9) 20 (17.7) 3.214 0.073

表2

唇腺病理阳性与阴性pSS患者免疫指标比较[n (%)]"

Variables Positive-pSS (n=104) Negative-pSS (n=113) Statistics P
ANA seropositive 101 (97.1) 111 (98.2) 0.009 0.925
  ANA titer = 1 ∶100 6 (5.8) 14 (12.4) 2.837 0.092
  ANA titer = 1 ∶320 9 (8.7) 20 (17.7) 3.723 0.054
  ANA titer = 1 ∶1 000 19 (18.3) 26 (23.0) 0.740 0.390
  ANA titer ≥ 1 ∶3 200 67 (64.4) 51 (45.1) 8.123 0.004
Anti-SSA 86 (82.7) 98 (86.7) 0.683 0.408
Anti-Ro-52 87 (83.7) 90 (79.6) 0.579 0.447
Anti-SSB 48 (46.2) 34 (30.1) 5.946 0.015
AMA-M2 8 (7.7) 15 (13.3) 1.781 0.182
Anti-CENP-B 8 (7.7) 10 (8.9) 0.095 0.757
Anti-RNP/Sm 11 (10.6) 12 (10.6) 0.000 0.992
Anti-dsDNA 0 1 (0.9)
Anti-CCP 1/40 (2.5) 2/43 (4.7) >0.999
IgG>1 600 mg/dL 71/96 (74.0) 60/99 (60.6) 3.941 0.047
IgA>450 mg/dL 18/96 (18.8) 13/99 (13.1) 1.151 0.283
IgM>270 mg/dL 9/96 (9.4) 7/99 (7.1) 0.344 0.558
C3 < 80 mg/dL 43/96 (44.8) 37/97 (38.1) 0.878 0.349
C4 < 16 mg/dL 36/96 (37.5) 33/97 (34.0) 0.254 0.614
RF seropositive 70/96 (72.9) 56/97 (57.7) 4.909 0.027
ESR>20 mm/h 48/83 (57.8) 31/82 (37.8) 6.629 0.010
CRP>0.8 mg/dL 9/94 (9.6) 5/97 (5.2) 1.373 0.241

表3

pSS患者病理阳性相关性因素分析"

Variables OR (95%CI) P value
Rampant caries 1.608 (0.723-3.576) 0.245
ANA titer ≥ 1 ∶3 200 1.592 (0.838-3.025) 0.155
Anti-SSB positive 1.190 (0.616-2.299) 0.604
ESR>20 mm/h 2.239 (0.657-2.337) 0.508
IgG>1 600 mg/dL 1.635 (0.813-3.290) 0.168
RF seropositive 0.875 (0.448-1.710) 0.696
ESSDAI
  ESSDAI < 5 Reference
  5≤ESSDAI < 10 0.711 (0.357-1.419) 0.334
  ESSDAI≥10 1.554 (0.723-3.340) 0.259
1 张文, 厉小梅, 徐东, 等. 原发性干燥综合征诊疗规范[J]. 中华内科杂志, 2020, 59 (4): 269- 270.
doi: 10.3760/cma.j.cn112138-20200113-00021
2 Mariette X , Criswell LA . Primary Sjögren' s syndrome[J]. N Engl J Med, 2018, 378 (10): 931- 939.
doi: 10.1056/NEJMcp1702514
3 Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren' s syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Ann Rheum Dis, 2017, 76 (1): 9- 16.
doi: 10.1136/annrheumdis-2016-210571
4 Seror R , Ravaud P , Bowman SJ , et al. EULAR Sjögren' s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2010, 69 (6): 1103- 1109.
doi: 10.1136/ard.2009.110619
5 Vitali C , Bombardieri S , Jonsson R , et al. Classification criteria for Sjögren' s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61 (6): 554- 558.
doi: 10.1136/ard.61.6.554
6 Guellec D , Cornec D , Jousse-Joulin S , et al. Diagnostic value of labial minor salivary gland biopsy for Sjögren' s syndrome: A systematic review[J]. Autoimmun Rev, 2013, 12 (3): 416- 420.
doi: 10.1016/j.autrev.2012.08.001
7 Fisher BA , Jonsson R , Daniels T , et al. Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2017, 76 (7): 1161- 1168.
doi: 10.1136/annrheumdis-2016-210448
8 Retamozo S , Acar-Denizli N , Rasmussen A , et al. Systemic manifestations of primary Sjögren' s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients[J]. Clin Exp Rheumatol, 2019, 37 (3/Suppl 118): 97- 106.
9 Luppi F , Sebastiani M , Silva M , et al. Interstitial lung disease in Sjögren' s syndrome: A clinical review[J]. Clin Exp Rheumatol, 2020, 38 (4/Suppl 126): 291- 300.
10 Lin W , Xin Z , Ning X , et al. Clinical features and risk factors of Raynaud' s phenomenon in primary Sjögren' s syndrome[J]. Clin Rheumatol, 2021, 40 (10): 4081- 4087.
doi: 10.1007/s10067-021-05749-w
11 Sharma R , Chaudhari KS , Kurien BT , et al. Sjögren syndrome without focal lymphocytic infiltration of the salivary glands[J]. J Rheumatol, 2020, 47 (3): 394- 399.
doi: 10.3899/jrheum.181443
12 Park Y , Lee J , Koh JH , et al. Positive histopathologic assessment in salivary glands shows little impact on clinical features of established primary Sjögren' s syndrome in a Korean population[J]. Clin Exp Rheumatol, 2020, 38 (4/ Suppl 126):): 158- 165.
13 Risselada AP , Kruize AA , Goldschmeding R , et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren' s syndrome[J]. Ann Rheum Dis, 2014, 73 (8): 1537- 1540.
doi: 10.1136/annrheumdis-2013-204634
14 Kakugawa T , Sakamoto N , Ishimoto H , et al. Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren' s syndrome[J]. Respir Med, 2018, 137, 95- 102.
doi: 10.1016/j.rmed.2018.02.023
15 Wu S , Tang X , Wu L , et al. Anti-Ro52 antibodies in clinical practice: A single-centre experience[J]. Int J Clin Pract, 2021, 75 (3): e13679.
[1] 刘源, 石桂秀. 干燥综合征到干燥病的命名变迁[J]. 北京大学学报(医学版), 2025, 57(6): 1015-1017.
[2] 林文灏, 谢阳, 王芳晴, 王淑盈, 刘香君, 胡凡磊, 贾园. 基于B细胞单细胞转录组测序的干燥综合征分子分型[J]. 北京大学学报(医学版), 2025, 57(6): 1032-1041.
[3] 向钊, 杨莉, 杨静. 非靶向代谢组学揭示原发性干燥综合征血小板减少患者血清差异代谢物及代谢通路[J]. 北京大学学报(医学版), 2025, 57(6): 1042-1050.
[4] 赵亚云, 倪梦凡, 李雪, 王蓓, 程功, 何菁, 金月波. 利妥昔单抗治疗原发性干燥综合征肾损害的临床疗效和安全性[J]. 北京大学学报(医学版), 2025, 57(6): 1051-1060.
[5] 朱丽秀, 陈仁利, 周素娟, 林烨, 汤一榕, 叶桢. 水通道蛋白5对干燥综合征大鼠TLR4/MyD88/NF-κB信号的影响[J]. 北京大学学报(医学版), 2025, 57(5): 875-883.
[6] 宁圆, 张晓盈, 李雪, 李原, 何菁, 金月波. 干燥综合征并发乳腺淋巴瘤1例[J]. 北京大学学报(医学版), 2025, 57(4): 808-811.
[7] 杨玉淑, 齐晅, 丁萌, 王炜, 郭惠芳, 高丽霞. 抗唾液腺蛋白1抗体联合抗腮腺分泌蛋白抗体对干燥综合征的诊断价值[J]. 北京大学学报(医学版), 2024, 56(5): 845-852.
[8] 韩艺钧,李常虹,陈秀英,赵金霞. 抗SSB抗体阳性和阴性的原发性干燥综合征患者临床及免疫学特征的比较[J]. 北京大学学报(医学版), 2023, 55(6): 1000-1006.
[9] 李建斌,吕梦娜,池强,彭一琳,刘鹏程,吴锐. 干燥综合征患者发生重症新型冠状病毒肺炎的早期预测[J]. 北京大学学报(医学版), 2023, 55(6): 1007-1012.
[10] 孟彦宏,陈怡帆,周培茹. CENP-B抗体阳性的原发性干燥综合征患者的临床和免疫学特征[J]. 北京大学学报(医学版), 2023, 55(6): 1088-1096.
[11] 吴洁,张雯,梁舒,秦艺璐,范文强. 妊娠期原发性干燥综合征合并视神经脊髓炎谱系疾病危重症1例[J]. 北京大学学报(医学版), 2023, 55(6): 1118-1124.
[12] 王丽芳,石连杰,宁武,高乃姝,王宽婷. 干燥综合征合并冷凝集素病1例[J]. 北京大学学报(医学版), 2023, 55(6): 1130-1134.
[13] 邢海霞,王琳,乔迪,刘畅,潘洁. 干燥综合征口腔疾病的治疗特点[J]. 北京大学学报(医学版), 2023, 55(5): 929-933.
[14] 刘杨,程昉,王艳玲,艾香艳,朱振航,赵福涛. 唾液腺超声对干燥综合征的诊断价值[J]. 北京大学学报(医学版), 2022, 54(6): 1123-1127.
[15] 于昊哲,曾唯珍,吴文雨,姚中强,冯云. 原发性干燥综合征合并甲状腺功能减退眼表状态评估[J]. 北京大学学报(医学版), 2022, 54(4): 705-711.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!